Physician profile
Wael Asi
NPI 1578551537
$9,023.61
in general payments reported to CMS, 2019-2025
47 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,657 · 2020: $888 · 2021: $235 · 2022: $1,421 · 2023: $1,826 · 2024: $1,501 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.57 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $901.00 | 2019-2024 | Yupelri |
| Abbvie INC. | $886.43 | 2022-2024 | Teflaro, Avycaz, Dalvance |
| Actelion Pharmaceuticals US, INC. | $847.34 | 2019-2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $821.60 | 2021-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $813.45 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $502.36 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $419.33 | 2019-2025 | |
| Insmed, INC. | $399.89 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.13 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Amgen INC. | $253.80 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $253.43 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.79 | 2022-2025 | Aralast, Glassia |
| Regeneron Healthcare Solutions, INC. | $213.85 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $205.84 | 2019-2025 | Keytruda, Winrevair, Zerbaxa |
| Jazz Pharmaceuticals INC. | $187.82 | 2020-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $175.76 | 2025 | Yupelri |
| Harmony Biosciences LLC | $161.15 | 2023-2025 | Wakix |
| Gilead Sciences, INC. | $134.61 | 2019-2024 | Veklury |
| Genentech USA, INC. | $134.26 | 2019-2025 | Xolair |
| Philips North America LLC | $128.15 | 2019-2025 | Vest Therapy Und |
| Grifols USA, LLC | $110.70 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $90.26 | 2019-2025 | Tyvaso |
| Pulmonx Corporation | $72.24 | 2023-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Optinose US, INC. | $70.04 | 2019-2025 | |
| Pfizer INC. | $64.94 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.67 | 2019-2022 | |
| Intersect Ent, INC. | $56.03 | 2019 | |
| Electromed, INC. | $55.39 | 2019-2021 | |
| Baxter Healthcare | $46.95 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Inogen, INC. | $37.29 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Octapharma USA, INC. | $32.50 | 2022 | |
| Tactile Systems Technology INC | $29.79 | 2022 | |
| Ani Pharmaceuticals, INC. | $26.94 | 2025 | Purified Cortrophin Gel |
| Allergan, INC. | $24.06 | 2020 | |
| Mallinckrodt Hospital Products INC. | $21.71 | 2022 | |
| Abbott Laboratories | $21.32 | 2022 | |
| Resmed Corp | $21.07 | 2025 | |
| Sunovion Pharmaceuticals INC. | $18.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.35 | 2019 | |
| Circassia INC. | $16.07 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.88 | 2025 | Alymsys |
| Liquidia Technologies, INC. | $15.11 | 2025 | Yutrepia |
| E.R. Squibb & Sons, L.L.C. | $14.66 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.19 | 2023 | Nuzyra |
| Eisai INC. | $12.95 | 2020 | |
| Biomerieux INC | $10.96 | 2019 | |
| Ethicon US, LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Asi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.